Ritlecitinib (PF-06651600)

Ritlecitinib (PF-06651600) (CAS No.: 1792180-81-4) is a synthetic small molecule kinase probe in the immunology and inflammation research category, characterized as a highly selective Janus kinase 3 inhibitor with irreversible covalent engagement of the JAK3 catalytic domain, and it is widely used in biomedical research to dissect common gamma chain cytokine signaling networks and downstream transcriptional responses; across biochemical and cellular profiling systems, its activity is reported in the nanomolar range for JAK3 while showing minimal inhibition of JAK1, JAK2, and TYK2 in the micromolar to greater than ten micromolar range, supporting utility for selective pathway interrogation with reduced off target JAK family interference; mechanistically, JAK3 blockade attenuates signaling initiated by cytokines such as IL 2 and IL 15 and reduces downstream STAT phosphorylation cascades, thereby enabling controlled investigation of lymphocyte activation programs, including Th1 and Th17 differentiation and effector function; in translationally oriented preclinical pharmacology, this compound has been applied in cell based assays and animal models of immune dysregulation and inflammatory or autoimmune like phenotypes to evaluate target engagement, pathway dependence, and pharmacodynamic biomarkers, while experimental concentrations or in vivo dose levels are typically selected according to study design, model context, and specific research objectives in drug discovery workflows.